These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 36263799)

  • 1. Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G.
    Anderson M; Stec M; Gosha A; Mohammad T; Boler M; Tojo Suarez R; Behun D; Landay A; Cloherty G; Moy J
    J Infect Dis; 2022 Nov; 226(11):1934-1942. PubMed ID: 36263799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durability of anti-spike antibodies after vaccination with mRNA SARS-CoV-2 vaccine is longer in subjects with previous infection: could the booster dose be delayed?
    Stellini R; Gianello R; Gomarasca W
    Infection; 2022 Dec; 50(6):1573-1577. PubMed ID: 35391649
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination.
    Dobaño C; Ramírez-Morros A; Alonso S; Ruiz-Olalla G; Rubio R; Vidal M; Prados de la Torre E; Jairoce C; Mitchell RA; Barrios D; Jiménez A; Rodrigo Melero N; Carolis C; Izquierdo L; Zanoncello J; Aguilar R; Vidal-Alaball J; Moncunill G; Ruiz-Comellas A
    Immunology; 2022 Dec; 167(4):528-543. PubMed ID: 36065677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence and Protective Potential of SARS-CoV-2 Antibody Levels After COVID-19 Vaccination in a West Virginia Nursing Home Cohort.
    Smoot K; Yang J; Tacker DH; Welch S; Khodaverdi M; Kimble W; Wen S; Amjad A; Marsh C; Perrotta PL; Hodder S
    JAMA Netw Open; 2022 Sep; 5(9):e2231334. PubMed ID: 36098966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between specific antibody response to wild-type BNT162b2 booster and the risk of breakthrough infection with omicron variants: Impact of household exposure in hospital healthcare workers.
    Tani N; Ikematsu H; Goto T; Kondo S; Gondo K; Fujiyoshi N; Minami J; Harada Y; Nagano S; Horiuchi T; Kuwano H; Akashi K; Shimono N; Chong Y
    Vaccine; 2023 Oct; 41(45):6672-6678. PubMed ID: 37775465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Healthcare Workers in South Korea Maintain a SARS-CoV-2 Antibody Response Six Months After Receiving a Second Dose of the BNT162b2 mRNA Vaccine.
    Choi JH; Kim YR; Heo ST; Oh H; Kim M; Lee HR; Yoo JR
    Front Immunol; 2022; 13():827306. PubMed ID: 35173736
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the neutralizing antibodies after the booster dose on SARS-CoV-2 Omicron variant and a two-year longitudinal antibody study on Wild Type convalescents.
    Zheng Y; Pan J; Jin M; Wang J; Tung TH; Chen S; Bi X; Zhou K; Chen M; Wang D; Li J; Shen B; Ying L
    Int Immunopharmacol; 2023 Jun; 119():110151. PubMed ID: 37044040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination.
    Martín Pérez C; Aguilar R; Jiménez A; Salmerón G; Canyelles M; Rubio R; Vidal M; Cuamba I; Barrios D; Díaz N; Santano R; Serra P; Santamaria P; Izquierdo L; Trilla A; Vilella A; Barroso S; Tortajada M; García-Basteiro AL; Moncunill G; Dobaño C
    BMC Med; 2024 Mar; 22(1):103. PubMed ID: 38454385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of anti-nucleocapsid antibody assays for the detection of SARS-CoV-2 Omicron vaccine breakthroughs after various intervals since the infection.
    Springer DN; Reuberger E; Borsodi C; Puchhammer-Stöckl E; Weseslindtner L
    J Med Virol; 2023 Nov; 95(11):e29229. PubMed ID: 37966995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
    Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
    Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2 Anti-Spike IgG Antibody and ACE2 Receptor Binding Inhibition Levels among Breakthrough Stage Veteran Patients.
    Chensue SW; Siler AF; Kim PS; Dimcheff DE; Daghfal DJ; Prostko J; Frias E; Linder KA; Schildhouse RJ
    Microbiol Spectr; 2022 Dec; 10(6):e0274722. PubMed ID: 36409132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal Follow-Up of the Immunity to SARS-CoV-2 in Health Care Workers in Argentina: Persistence of Humoral Response and Neutralizing Capacity after Sputnik V Vaccination.
    Castro EF; Acosta J; Moriena L; Rios Medrano M; Tejerina Cibello M; Codino E; Taborda MÁ; Álvarez DE; Cavatorta AL
    mSphere; 2023 Jun; 8(3):e0066222. PubMed ID: 37070983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.
    Sughayer MA; Souan L; Abu Alhowr MM; Al Rimawi D; Siag M; Albadr S; Owdeh M; Al Atrash T
    Vaccine; 2022 May; 40(20):2841-2847. PubMed ID: 35397946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-vaccination SARS-CoV-2 IgG spike antibody responses among clinical and non-clinical healthcare workers at a tertiary facility in Kenya.
    Mwangi LW; Omuse G; Adam R; Ong'ete G; Matheka C; Mugaine P; Sayed S; Maina D
    PLoS One; 2024; 19(4):e0299302. PubMed ID: 38573911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association Between Low Anti-spike Antibody Levels After the Third Dose of SARS-CoV-2 Vaccination and Hospitalization due to Symptomatic Breakthrough Infection in Kidney Transplant Recipients.
    Han A; Min S; Jo EA; Lee H; Kim YC; Han SS; Kang HG; Ahn YH; Oh I; Song EY; Ha J
    Ann Lab Med; 2024 Jan; 44(1):64-73. PubMed ID: 37665287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 vaccine antibody response and breakthrough infections in transplant recipients.
    Vanlerberghe B; Vrij C; Bogaerts K; Vermeersch P; Lagrou K; Molenberghs G; Rega F; Ceulemans LJ; van Raemdonck D; Jochmans I; Monbaliu D; Pirenne J; Vanuytsel T; Gillard P; Schoemans H; Cleemput JV; Kuypers D; Vos R; Nevens F; Verbeek J
    J Med Virol; 2023 Apr; 95(4):e28736. PubMed ID: 37185854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
    Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
    Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omicron neutralizing antibody response following booster vaccination compared with breakthrough infection.
    Curlin ME; Bates TA; Guzman G; Schoen D; McBride SK; Carpenter SD; Tafesse FG
    Med; 2022 Dec; 3(12):827-837.e3. PubMed ID: 36198311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody Responses to the BNT162b2 mRNA Vaccine in Healthcare Workers in a General Hospital in Japan: A Comparison of Two Assays for Anti-spike Protein Immunoglobulin G.
    Hibino M; Watanabe S; Kamada R; Tobe S; Maeda K; Horiuchi S; Kondo T
    Intern Med; 2022 Mar; 61(6):811-819. PubMed ID: 34980798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.